Status:
COMPLETED
Cardiovascular Outcome After Surgery or Somatostatin Analogues
Lead Sponsor:
Federico II University
Conditions:
Acromegaly
Eligibility:
All Genders
18-85 years
Brief Summary
A direct comparison between the results of surgery or somatostatin analogues (SSA) on cardiovascular complication in acromegaly has never been performed. Our objective is to investigate whether first...
Detailed Description
We will review all files from consecutive patients with active acromegaly coming to the Units of Endocrinology or Neurosurgery of the "Federico II" University of Naples from Jan 1st 1997 to December 3...
Eligibility Criteria
Inclusion
- Patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach or with first-line depot SSA treatment
- Achieving control of the disease; AND
- With available follow-up after 12 months of treatment
Exclusion
- Patients receiving second surgery within 3 months from first surgery
- Requiring combined dopamine-agonists and SSA because of a mixed GH/PRL-secreting tumor
- Receiving the s.c. octreotide for longer than 15 days; OR
- Requiring surgery or SSA as second-line treatment before the completion of the 12 months or with a follow-up shorter than 6 months after surgery or pharmacotherapy
Key Trial Info
Start Date :
January 1 1997
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT00615004
Start Date
January 1 1997
End Date
December 1 2007
Last Update
February 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
Naples, Naples, Italy, 80131